A newly defined medical condition known as cardiovascular-kidney-metabolic (CKM) syndrome is estimated to affect nearly 90 percent of adults, according to data from the American Heart Association. Despite its widespread prevalence, the condition remains largely unknown to the public, with recent surveys indicating that approximately nine in ten adults have never heard of the term. The syndrome was formally defined by the American Heart Association in 2023 to better categorize the interconnected nature of heart disease, kidney disease, diabetes, and obesity.
CKM syndrome is not a single disease but a framework that recognizes how these health conditions influence and exacerbate one another. The syndrome is categorized into a four-stage continuum, ranging from Stage 0, where no risk factors are present, to Stage 4, which involves established cardiovascular disease and potential kidney failure. Common risk factors include high blood pressure, abnormal cholesterol levels, elevated blood sugar, and excess body weight.
Medical experts emphasize that the primary goal of this designation is to improve early detection and prevention. By identifying the overlap between these systems, clinicians can better manage patients who may have multiple, seemingly separate, health issues. The interplay of these risk factors is known to increase the likelihood of heart attack, stroke, and heart failure significantly more than any single condition acting in isolation.
For many individuals, the progression of CKM syndrome can be slowed or even reversed through lifestyle modifications, including improved nutrition and increased physical activity, alongside appropriate medical treatment. As awareness of the condition grows, health organizations are working to provide clearer guidelines for both patients and providers to manage these interconnected risks effectively.